Periorbital dermatitis, chronic actinic dermatitis, and erythema multiforme-like lesions were seen in 6, 3, and 2 patients, respectively.
Background: Given the current interest in vitamin D status and its suggested relationship to immune and metabolic outcomes, the accurate and reliable assessment of 25(OH)D concentrations in both research and clinical settings is imperative. CIA is routinely used in most laboratories whereas LC-MS/MS is defined as the gold standard. However, studies in adults have been performed detecting substantial variation in the measured 25(OH)D3 levels comparing both methods.
We are currently conducting the first RCT on vitamin D status in infancy and allergic outcome in early childhood. Vitamin D deficiency is known to be a major problem in Australia and particularly in infants. We therefore used this study cohort as an opportunity to compare CIA and LC-MS/MS methodology. To our knowledge no studies have investigated this before in infants.
Methods:
In this DBPC trial, high risk infants are orally supplemented with either 400 IU vitamin D/day or placebo from birth to 6 months of age. Blood samples are collected at 3, 6 and 12 months of age to determine relationships between oral vitamin D supplementation and blood 25(OH) D concentration, immune cell function responses to allergens and on the development of allergic conditions in early childhood. In each subject 25(OH)D concentration was measured via CIA and LC-MS/MS. We used the Bland Altman Plot for analyzing CIA and LC-MS/MS.
Results: 25(OH)D3 levels were analysed by both methodologies (CIA and LC-MS/MS) in 68/120 infants at 3 months, 78/120 at 6 months and 73/120 at 12 months. The highest agreement between both methods was found in 3 months old infants (correlation between difference and mean −0.076), with still good agreement in 12 (correlation between difference and mean −0.251) but no agreement in 6 months old infants.
Conclusion: This is the first study in infants comparing the major 25(OH)D assays currently in use and accredited for clinical testing. Compared to adult studies we showed that there is a good agreement between CIA and LC-MS/MS. This knowledge is of particular value as vitamin D levels need to be very accurate and precise to guarantee sufficient bone growth and optimal immune function in utero and infancy. Differences in agreement dependent on the age of the infant may indicate that growth associated with immunological and metabolic changes may influence the assays. Further Paediatric studies comparing both assays in different age groups are warranted. Method: We have conducted a retrospective analysis of Western Australian patients prescribed omalizumab to facilitate VIT over the last 8 years. Using review of available medical records, we will describe this cohort, including medical co-morbidities, reaction characteristics, VIT protocols used, omalizumab dosing and outcomes.
P75 OMALIZUMAB USE IN BEE VENOM IMMUNOTHERAPY: A RETROSPECTIVE COHORT ANALYSIS
Results: A total of seven patients prescribed omalizumab to facilitate VIT over the last 8 years were identified, in addition to three patients who are intended for commencement of omalizumab (total n = 10). The mean and median patient age was 45 years (range = 35-55 years). There was an equal 50:50 split of male/female patients. Anaphylactic reaction was Grade 4 for 50%, Grade 3 for 30%, and Grade 2 for 20% of patients. The median baseline mast cell tryptase level was 5.1 with an interquartile range of 3.4 (LQ) -21.625 (UQ). All collected information has been tabulated, and further cohort analysis is ongoing.
Conclusion:
It is hoped that this information will allow us to identify patients who may requiring omalizumab in order to receive VIT and to determine optimum omalizumab/VIT protocols. The Immunology and Allergy Unit, Campbelltown Hospital, Sydney, Australia
P76 HEREDITARY ANGIOEDEMA ATTACK PROPHYLAXIS MANAGEMENT IN AUSTRALIAN PATIENTS
Purpose: Management of Hereditary Angioedema (HAE) has changed substantially in the last decade with the advent of new medications and improved access to replacement therapy with C1 inhibitor concentrate. Improvements in prophylactic therapy have resulted in patients having greater control over their condition and better quality of life. International guidelines are reflecting the shift to greater access to safer and more effective prophylaxis for this potentially life-threatening condition. We have surveyed ASCIA members involved in the care of patients with HAE to gauge the pattern of usage of prophylactic therapy.
Methods: A questionnaire was sent to members of ASCIA HAE Working Party and to other Immunologists known to have HAE patients in their care (n = 14). The questionnaire was returned, de-identified, by 13 specialists reporting on 102 HAE patients in their care. Usage patterns for prophylaxis with Berinert, Danazol and tranexamic acid were explored and results were tabulated.
Results: Six of 13 responding specialists had prescribed Berinert for long term prophylaxis (BLTP) to 18/102 (17%) patients. NBA prescription criteria were followed in all; 11 patients received 20 IU/kg while 2 received less, and 4 more, than this. Only 2/18 patients on BLTP had not received other prophylaxis in the past. No side effects were reported in any on BLTP; 17/18 patients were satisfied with control. Since using BLTP only 1 patient had had a hospitalisation and only 1 had seen no reduction in icatibant use whereas 12/18 had reduced icatibant use by >50%. Danazol was currently used in 36/102 patients and tranexamic acid in 19/102 patients.
Conclusion: BLTP is used currently in the minority of HAE patients receiving prophylactic therapy. It is well tolerated with the majority of patients self administering and its use has led to a reduction in acute treatment with icatibant. 
